UNSPSC 51284101: Cefcapene

This classification denotes a cephalosporin antibiotic with the molecular formula C17H19N5O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4D5D3422MW, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-7-((2-(2-amino-4-thiazolyl)-1-oxo-2-pentenyl)amino)-8-oxo-, (6r-(6alpha,7beta(z)))- but generally known as cefcapene, which bears US NIH Compound Identifier 6436055.

UNSPSC 51284101 Cefcapene is a Commodity code that does not reflect the actual scope of state and local procurement activity recently tagged under it. The recent opportunities posted under this code solicit naloxone and drug deactivation systems, therapeutic pharmacy initiative vendor capabilities, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and OTC products — none of which are cefcapene, a specific antibiotic active ingredient. The mismatch between the code's nominal scope and the work actually being bought suggests either data-entry error in the tagging system or a broader pharmaceutical-procurement classification being misapplied at the commodity level.

The issuing bodies soliciting under this code span state health and human services agencies (Texas Health and Human Services Commission), county public health (Seminole County, Florida), municipal emergency services (City of Tampa Fire Department), and multi-state cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance with Oregon participation). Recent opportunities include Seminole County's competitive bid for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery (IFB 60459723LAS, due July 26, 2023); the City of Tampa's invitation to bid for 169 line items of medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000 and a sheltered-market set-aside for certified Small Local Business Enterprises (IFB 26P00145, due March 13, 2026); the Texas HHS Commission's Request for Information on direct-to-manufacturer pharmacy prescription programs (RFI HHS0017013, April 3, 2026); and the Minnesota Department of Administration's multi-state RFP for generic pharmaceuticals and OTC products distributed through authorized wholesalers (RFP S1070000015802, due March 26, 2026, with contract start July 1, 2026). The code shows limited recent relevant activity; prospectors should verify actual procurement intent with issuing bodies rather than rely on this code's classification.